Published online Jun 15, 2021. doi: 10.4239/wjd.v12.i6.868
Peer-review started: February 2, 2021
First decision: February 25, 2021
Revised: March 12, 2021
Accepted: April 25, 2021
Article in press: April 25, 2021
Published online: June 15, 2021
Processing time: 122 Days and 0.2 Hours
Gestational diabetes mellitus (GDM) is the most common metabolic disorder of pregnancy. It is associated with both short- and long-term fetal, neonatal and maternal complications. Treatment of GDM has been shown to improve pregnancy outcomes.
Worldwide different diagnostic criteria to diagnose GDM are being used. Recently the Hyperglycemia and Adverse Pregnancy Outcome study has shown that maternal glucose levels below the most used thresholds increase the risk of adverse outcomes. As a result, new diagnostic criteria have been proposed by the World Health Organization (WHO) in 2013. These new, more stringent criteria have been shown to greatly affect the number of women diagnosed with GDM, which in turn can have great consequences for health care costs and effectiveness of current treatment strategies. However, the effects vary in different populations and are influenced by patient characteristics such as ethnicity and maternal body mass index.
We aimed to estimate the impact of the WHO 2013 criteria, compared with the WHO 1999 criteria, on the incidence of gestational diabetes mellitus as well as to determine the diagnostic accuracy for detecting adverse pregnancy outcomes. We sought to evaluate the patient characteristics and pregnancy outcomes of women with a discordant diagnosis specifically, as these are of importance for the treatment effects that may be expected. Currently, the treatment effects in these women are unknown.
For this study we evaluated a cohort of 3338 women that were tested for GDM using a 75 g oral glucose tolerance test in the University Medical Center Utrecht. We applied both the current WHO 1999 criteria and the newly proposed WHO 2013 criteria for GDM. We determined the change in the number of GDM diagnoses. Also, we separately reported on patient characteristics and pregnancy outcomes of women with discordant diagnoses and compared these to the non-GDM women. Lastly, we determined the likelihood ratios for adverse outcomes for the different groups.
Retrospectively applying the WHO 2013 criteria increased the cohort incidence by 13.1%, from 19.3 to 32.4%. Discordant diagnoses occurred in 21.3%; 4.1% would no longer be labelled as GDM, and 17.2% were newly diagnosed. Compared to the non-GDM group, women newly diagnosed were older, had higher rates of obesity, higher diastolic blood pressure and higher rates of caesarean deliveries. Their infants were more often delivered preterm, large-for-gestational-age and were at higher risk of a 5-min Apgar score < 7. Women excluded from GDM were older and had similar pregnancy outcomes compared to the non-GDM group, except for higher rates of shoulder dystocia (4.3% vs 1.3%, P = 0.015). Positive likelihood ratios for adverse outcomes in all groups were generally low, ranging from 0.54 to 2.95.
The number of women diagnosed with GDM increases substantially with the WHO 2013 compared to the WHO 1999 criteria. Women additionally diagnosed are at increased risk for adverse pregnancy outcomes. However, they seem to be at lower risk than women who would be diagnosed with GDM by both the old and new criteria. Also, likelihood ratios for adverse outcomes comparing both diagnostic criteria are generally low. Treatment effects may therefore be lower in newly diagnosed women, which may result in overtreatment of women newly diagnosed with GDM according to the WHO 2013 criteria.
Adopting the WHO 2013 criteria results in an increased number of women diagnosed with GDM and translates to an excess risk of adverse pregnancy outcomes, supporting the need for intervention studies to estimate the treatment benefit and cost-effectiveness to improve clinically relevant outcomes for these previously untreated pregnant women.